Eloctate 750 Unit

ELOCTATE 750 Unit is a recombinant antihemophilic factor used for hemophilia B treatment. This intravenous kit helps manage bleeding episodes and prevent surgical bleeding.

ELOCTATE 750 Unit is primarily used to control and prevent bleeding in patients with hemophilia B, a genetic disorder that affects blood clotting. It is often administered intravenously to manage bleeding episodes or to prevent bleeding during surgical procedures. This medication is designed to replace the missing clotting factor IX, which is essential for proper blood coagulation.

Common effects of ELOCTATE 750 Unit may include mild to moderate reactions at the injection site, such as redness or swelling. Some users may experience flu-like symptoms, including headache, fever, or chills. These effects are generally temporary and should be monitored. Severe allergic reactions are rare but require immediate medical attention.

ELOCTATE 750 Unit should be handled with care, ensuring proper storage and administration techniques. It is important to follow the instructions provided by a healthcare professional. Patients with known allergies to any components of the medication should avoid its use. Regular monitoring and consultation with a healthcare provider are recommended.

ELOCTATE 750 Unit may interact with certain medications, including those that affect blood clotting. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect blood clotting should be used with caution.